Ah Equity Partners V, L.L.C. Erasca, Inc. Transaction History
Ah Equity Partners V, L.L.C.
- $15.4 Million
- Q3 2022
A detailed history of Ah Equity Partners V, L.L.C. transactions in Erasca, Inc. stock. As of the latest transaction made, Ah Equity Partners V, L.L.C. holds 50,000 shares of ERAS stock, worth $55,000. This represents 2.53% of its overall portfolio holdings.
Number of Shares
50,000
Previous 50,000
-0.0%
Holding current value
$55,000
Previous $279,000
39.78%
% of portfolio
2.53%
Previous 1.21%
Shares
2 transactions
Others Institutions Holding ERAS
# of Institutions
162Shares Held
222MCall Options Held
20.6KPut Options Held
5.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.6MShares$24.8 Million1.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.3MShares$19 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$17.8 Million5.36% of portfolio
-
Logos Global Management LP San Francisco, CA13MShares$14.3 Million3.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$14 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $134M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...